Minhong Shen

Minhong Shen

Assistant Professor


Minhong Shen

Office Address

6304 Scott Hall
540 E Canfield
Detroit, Michigan 48201


The Shen lab is interested in understanding the interplay between tumor microenvironment (TME) remodeling and cancer treatment resistance. Therapeutic resistance that is frequently observed in metastatic cancers is one of the biggest hurdles in cancer treatment. Effective drugs that could achieve complete curative therapies are urgently needed. A growing body of evidence suggests that TME plays pivotal roles in cancer treatment responses. Our long-term research goal is to provide insights into the following two questions: 1) How does TME contribute to cancer treatment resistance; and 2) How could we remodel TME to enhance therapeutic responses. To this end, we are currently focusing on the following three areas: a) Investigate the role of extracellular matrix protein Tinagl1 in TME remodeling and evaluate its therapeutic potential; b) Identify novel candidates that are involved in TME modeling and the consequent treatment responses with high-throughput screening platforms we have established; and c) Develop new TME remodeling strategies to enhance cancer treatment responses by focusing on targeting protein-protein interaction, delivering antisense oligonucleotides, and using Adeno-associated virus mediated CRISPR/Cas9 system.

Shen lab website (positions are available)


B.S., Zhejiang University, 2008 (Biotechnology)
Ph.D., Zhejiang University, 2013 (Pathology and Pathophysiology)


Postdoctoral training, Princeton University (laboratory of Dr. Yibin Kang)


Shen M., Wei Y., Kim H., Wan L., Jiang Y., Hang X., Raba M., Remiszewski S., Rowicki M., Zhang L., Lu X., Yuan M., Smith H., Zheng A., Lin H., Bertino J., Jin J., Xing Y., Shao Z., Kang Y. (2021) Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis. Nature Cancer. https://doi.org/10.1038/s43018-021-00279-5

Shen M., Smith H., Wei Y., Jiang Y., Zhao S., Wang N., Rowicki M., Tang Y., Hang X., Wan L., Shao Z., Kang Y. (2021) Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nature Cancer. https://doi.org/10.1038/s43018-021-00280-y

Shen M., Xie S., Rowicki M., Michel S., Wei Y., Hang X., Wan L., Lu X., Yuan M., Jin JF., Jaschinski F., Zhou T., Klar R., Kang Y. (2021) Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis. Cancer Research DOI: 10.1158/0008-5472.CAN-20-1876.

Shen M., Kang Y. (2020) Stresses in the metastatic cascade: molecular mechanisms and therapeutic opportunities. Genes & Development 34 (23-24), 1577-1598.

Shen M., Jiang YZ., Wei Y., Ell B., Sheng X., Esposito M., Kang J., Hang X., Zheng H., Rowicki M., Zhang L., Shih WJ., Celia-Terrassa T., Liu Y., Shao ZM., Crestea I., Kang Y. (2019) Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. Cancer Cell. 35(1): 64-80.

Shen M., Kang Y. (2019) Role Reversal: A Pro-metastatic Function of E-Cadherin. Developmental Cell 51 (4), 417-419

Shen M., Kang, Y. (2018) pSTAT3+ Reactive Astrocytes Promote Brain Metastasis. Trends Mol Med. pii: S1471-4914(18)30141-2.

Shen M., Kang, Y. (2018) The Complex Interplay between the Tumor Microenvironment and Cancer Therapy. Frontiers of Medicine. 12: 426-439.

Feng S*., Song Y*., Shen M*., Xie S*., Li W., Yang Y., Zhou J., Wang F., Ou G., Yan X., Liang X., Lu Y., Zhou T. (2017) Microtubule-binding protein FOR20 promotes microtubule depolymerization and cell migration. Cell Discovery doi:10.1038/celldisc.2017.32. (*co-first author)

Shen M., Cai Y., Yan X., Yang Y., Zhou T. (2013) Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes. Cell Research 23:1284-1295

Complete list of publications can be found here

← Return to listing